Shaftesbury (LON:SHB) Hit By JP Morgan Cazenove Downgrade; Wavetrue (PRTK)’s Sentiment Is 1.54

In a a report sent to clients and investors on Monday, 15 January, JP Morgan Cazenove stated it was downgrading Shaftesbury (LON:SHB) stock rating to a “Neutral”.

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. The company has market cap of $498.75 million. The Company’s lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections , community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea. It currently has negative earnings. The firm has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP.

Abingworth Llp holds 18.09% of its portfolio in Paratek Pharmaceuticals, Inc. for 1.04 million shares. Roumell Asset Management Llc owns 101,399 shares or 5.99% of their US portfolio. Moreover, Broadfin Capital Llc has 1.51% invested in the company for 406,207 shares. The New York-based Opus Point Partners Management Llc has invested 0.9% in the stock. General American Investors Co Inc, a New York-based fund reported 347,213 shares.

The stock decreased 1.92% or $0.35 during the last trading session, reaching $17.85. About 265,386 shares traded. Paratek Pharmaceuticals, Inc. (PRTK) has risen 62.03% since January 15, 2017 and is uptrending. It has outperformed by 45.33% the S&P500.

Analysts await Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) to report earnings on March, 1. They expect $-0.72 EPS, up 37.93% or $0.44 from last year’s $-1.16 per share. After $-0.77 actual EPS reported by Paratek Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -6.49% EPS growth.

Shaftesbury PLC, a real estate investment trust, engages in the investment, ownership, and lease of properties in London, the United Kingdom. The company has market cap of 3.09 billion GBP. The firm owns and leases shops, restaurants and leisure space, offices, and residential properties. It has a 9.33 P/E ratio. The Company’s property portfolio comprises approximately 453,000 square feet of restaurants, bars, and leisure spaces; and 394,000 square feet of retail accommodation, 424,000 square feet of offices, and 345 apartments covering 233,000 square feet.

The stock decreased 0.79% or GBX 8 during the last trading session, reaching GBX 1007. About 93,163 shares traded. Shaftesbury PLC (LON:SHB) has 0.00% since January 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 17 analysts covering Shaftesbury (LON:SHB), 3 have Buy rating, 5 Sell and 9 Hold. Therefore 18% are positive. Shaftesbury has GBX 1150 highest and GBX 760 lowest target. GBX 968.35’s average target is -3.84% below currents GBX 1007 stock price. Shaftesbury had 151 analyst reports since August 3, 2015 according to SRatingsIntel. BNP Paribas upgraded Shaftesbury PLC (LON:SHB) on Friday, January 8 to “Neutral” rating. The rating was maintained by Jefferies with “Hold” on Wednesday, November 30. Numis Securities maintained Shaftesbury PLC (LON:SHB) rating on Thursday, May 25. Numis Securities has “Hold” rating and GBX 974 target. Liberum Capital maintained the stock with “Buy” rating in Wednesday, September 30 report. On Friday, January 29 the stock rating was maintained by Canaccord Genuity with “Hold”. The firm has “Overweight” rating given on Thursday, July 21 by JP Morgan. The company was maintained on Wednesday, September 27 by Goldman Sachs. The firm earned “Neutral” rating on Friday, February 5 by UBS. The rating was maintained by Liberum Capital with “Buy” on Monday, March 13. As per Tuesday, December 6, the company rating was maintained by Numis Securities.